Hikma Pharmaceuticals Plc Goodwill and Intangible Assets 2016-2024 | HKMPF

Hikma Pharmaceuticals Plc goodwill and intangible assets for the quarter ending June 30, 2024 were $1.100B, a 21.41% increase year-over-year.

  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2023 were $1.1B, a 2.14% decline from 2022.
  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2022 were $1.124B, a 26.01% increase from 2021.
  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2021 were $0.892B, a 1.83% increase from 2020.

Hikma Pharmaceuticals Plc Goodwill and Intangible Assets 2016-2024 | HKMPF

  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2023 were $1.1B, a 2.14% decline from 2022.
  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2022 were $1.124B, a 26.01% increase from 2021.
  • Hikma Pharmaceuticals Plc goodwill and intangible assets for 2021 were $0.892B, a 1.83% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.8B
Chugai Pharmaceutical (CHGCY)$66.9B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$20B
Astellas Pharma (ALPMY)$17.7B
United Therapeutics (UTHR)$16.6B
Summit Therapeutics (SMMT)$16B
Neurocrine Biosciences (NBIX)$15.3B
Shionogi (SGIOY)$12.5B
Orion OYJ (ORINY)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.1B
Stevanato Group S.p.A (STVN)$6.5B
Corcept Therapeutics (CORT)$6.4B
Ionis Pharmaceuticals (IONS)$5.2B
Ono Pharmaceutical (OPHLF)$4.9B
Grifols, S.A (GRFS)$4.8B
Crinetics Pharmaceuticals (CRNX)$3.7B
Catalyst Pharmaceuticals (CPRX)$2.9B
Recursion Pharmaceuticals (RXRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.1B
Hypermarcas (HYPMY)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Indivior (INDV)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
Evotec AG (EVO)$1.5B
Guardian Pharmacy Services (GRDN)$1.4B
ARS Pharmaceuticals (SPRY)$1.4B